Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species.
The activity of prostacyclin (PGI2), PGE1 or PGD2 as inhibitors of platelet aggregation in plasma from human, dog, rabbit, rat, sheep and horse was investigated. Prostacyclin was the most potent inhibitor in all species. PGD2 was a weak inhibitor in dog, rabbit and rat plasma whereas PGE1 and prostacyclin were highly active. Theophylline or dipyridamole potentiated the inhibition of human platelet aggregation by prostacyclin, PGE1 or PGD2. Compound N-0164 abolished the inhibition by PGD2 of human platelet aggregation but did not inhibit the effects of PGE1 or prostacyclin. The results suggest that prostacyclin and PGE1 act on similar sites on platelets which are distinct from those for PGD2.
D000818:Animals; D004176:Dipyridamole / Q000494:pharmacology; D004285:Dogs; D011464:Epoprostenol / Q000494:pharmacology*; D006736:Horses; D006801:Humans; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects*; D011448:Prostaglandin Antagonists / Q000494:pharmacology; D011453:Prostaglandins / Q000494:pharmacology*; D011457:Prostaglandins D / Q000494:pharmacology*; D011458:Prostaglandins E / Q000494:pharmacology*; D011817:Rabbits; D051381:Rats; D012310:Ristocetin / Q000494:pharmacology; D012756:Sheep; D013045:Species Specificity; D013806:Theophylline / Q000494:pharmacology
D063065:Organophosphonates; D009943:Organophosphorus Compounds; D011448:Prostaglandin Antagonists; D011453:Prostaglandins; D011457:Prostaglandins D; D011458:Prostaglandins E; D012310:Ristocetin; C012641:N 0164; D004176:Dipyridamole; D013806:Theophylline; D011464:Epoprostenol